$BPMC (-8.7% pre) Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results https://t.co/9blcmO93bN
$BPMC now predicting $4bn peak revenues for Ayvakit ($2bn by 2030)
$BPMC Blueprint Medicines Q4 2024 GAAP EPS $(0.79) Misses $(0.70) Estimate Sales $146.37M Beat $145.84M Estimate
Blueprint Medicines Corporation ($BPMC) reported its fourth quarter and full year 2024 results, revealing global net product revenues of $479.0 million for AYVAKIT® (avapritinib), including $144.1 million in the fourth quarter. The company reported a GAAP EPS of $(0.79), which missed the estimated $(0.70). However, sales of $146.37 million surpassed the estimate of $145.84 million. Looking ahead, Blueprint Medicines anticipates global AYVAKIT net product revenue to be between $680 million and $710 million in 2025, with peak revenues projected at $4 billion, including $2 billion by 2030. Following the announcement, the company's stock fell by 8.7% in pre-market trading.
